1. Home
  2. HSII vs ARDX Comparison

HSII vs ARDX Comparison

Compare HSII & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heidrick & Struggles International Inc.

HSII

Heidrick & Struggles International Inc.

HOLD

Current Price

$59.01

Market Cap

1.2B

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$6.23

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HSII
ARDX
Founded
1953
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.5B
IPO Year
1999
2014

Fundamental Metrics

Financial Performance
Metric
HSII
ARDX
Price
$59.01
$6.23
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$57.50
$10.65
AVG Volume (30 Days)
430.9K
2.7M
Earning Date
11-03-2025
10-30-2025
Dividend Yield
1.02%
N/A
EPS Growth
N/A
N/A
EPS
1.73
N/A
Revenue
$1,199,854,000.00
$398,234,000.00
Revenue This Year
$13.60
$22.71
Revenue Next Year
N/A
$27.81
P/E Ratio
$34.12
N/A
Revenue Growth
11.56
58.12
52 Week Low
$36.87
$3.21
52 Week High
$59.05
$6.78

Technical Indicators

Market Signals
Indicator
HSII
ARDX
Relative Strength Index (RSI) 77.94 62.17
Support Level $58.84 $5.77
Resistance Level $59.05 $6.20
Average True Range (ATR) 0.09 0.27
MACD -0.11 0.03
Stochastic Oscillator 89.74 91.30

Price Performance

Historical Comparison
HSII
ARDX

About HSII Heidrick & Struggles International Inc.

Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: